| 1. |
郭偉, 李鑫, 王明達, 等. 《腫瘤外科學年鑒: 肝外膽管癌和膽囊癌臨床診療指南》推薦意見. 臨床肝膽病雜志, 2024, 40(4): 682-687.
|
| 2. |
Vuthaluru S, Sharma P, Chowdhury S, et al. Global epidemiological trends and variations in the burden of gallbladder cancer. J Surg Oncol, 2023, 128(6): 980-988.
|
| 3. |
王一鈞, 孫旭恒, 馮佳毅, 等. 2010-2017年中國膽囊癌診治流程與預后分析 (附7 874例報告). 中國實用外科雜志, 2024, 44(9): 1038-1054, 1061.
|
| 4. |
Piccolo G, Barabino M, Piozzi GN, et al. Radical cholecystectomy without liver resection for peritoneal side early incidental gallbladder cancer. World J Gastroenterol, 2024, 30(32): 3739-3742.
|
| 5. |
Roa JC, García P, Kapoor VK, et al. Gallbladder cancer. Nat Rev Dis Primers, 2022, 8(1): 69. doi: 10.1038/s41572-022-00398-y.
|
| 6. |
Wistuba II, Gazdar AF. Gallbladder cancer: lessons from a rare tumour. Nat Rev Cancer, 2004, 4(9): 695-706.
|
| 7. |
Sharma A, Sharma KL, Gupta A, et al. Gallbladder cancer epidemiology, pathogenesis and molecular genetics: recent update. World J Gastroenterol, 2017, 23(22): 3978-3998.
|
| 8. |
Ilyas SI, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol, 2018, 15(2): 95-111.
|
| 9. |
Jain K, Sreenivas V, Velpandian T, et al. Risk factors for gallbladder cancer: a case-control study. Int J Cancer, 2013, 132(7): 1660-1666.
|
| 10. |
Nejman D, Livyatan I, Fuks G, et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science, 2020, 368(6494): 973-980.
|
| 11. |
Yang L, Li A, Wang Y, et al. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal Transduct Target Ther, 2023, 8(1): 35. doi: 10.1038/s41392-022-01304-4.
|
| 12. |
Galeano Ni?o JL, Wu H, LaCourse KD, et al. Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer. Nature, 2022, 611(7937): 810-817.
|
| 13. |
Xue C, Chu Q, Zheng Q, et al. Current understanding of the intratumoral microbiome in various tumors. Cell Rep Med, 2023, 4(1): 100884. doi: 10.1016/j.xcrm.2022.100884.
|
| 14. |
de Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol, 2012, 13(6): 607-615.
|
| 15. |
Plummer M, de Martel C, Vignat J, et al. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Glob Health, 2016, 4(9): e609-e616.
|
| 16. |
Zhang J, Wang P, Wang J, et al. Unveiling intratumoral microbiota: an emerging force for colorectal cancer diagnosis and therapy. Pharmacol Res, 2024, 203: 107185. doi: 10.1016/j.phrs.2024.107185.
|
| 17. |
Zhao X, Zhao J, Li D, et al. Akkermansia muciniphila: a potential target and pending issues for oncotherapy. Pharmacol Res, 2023, 196: 106916. doi: 10.1016/j.phrs.2023.106916.
|
| 18. |
Wang M, Yu F, Li P. Intratumor microbiota in cancer pathogenesis and immunity: from mechanisms of action to therapeutic opportunities. Front Immunol, 2023, 14: 1269054. doi: 10.3389/fimmu.2023.1269054.
|
| 19. |
Phipps O, Quraishi MN, Dickson EA, et al. Differences in the on- and off-tumor microbiota between right- and left-sided colorectal cancer. Microorganisms, 2021, 9(5): 1108. doi: 10.3390/microorganisms9051108.
|
| 20. |
Yuan L, Yang P, Wei G, et al. Tumor microbiome diversity influences papillary thyroid cancer invasion. Commun Biol, 2022, 5(1): 864. doi: 10.1038/s42003-022-03814-x.
|
| 21. |
He Y, Zhang Q, Yu X, et al. Overview of microbial profiles in human hepatocellular carcinoma and adjacent nontumor tissues. J Transl Med, 2023, 21(1): 68. doi: 10.1186/s12967-023-03938-6.
|
| 22. |
Chai X, Wang J, Li H, et al. Intratumor microbiome features reveal antitumor potentials of intrahepatic cholangiocarcinoma. Gut Microbes, 2023, 15(1): 2156255. doi: 10.1080/19490976.2022.2156255.
|
| 23. |
Tsuchiya Y, Loza E, Villa-Gomez G, et al. Metagenomics of microbial communities in gallbladder bile from patients with gallbladder cancer or cholelithiasis. Asian Pac J Cancer Prev, 2018, 19(4): 961-967. doi: 10.22034/APJCP.2018.19.4.961.
|
| 24. |
Song X, Wang X, Hu Y, et al. A metagenomic study of biliary microbiome change along the cholecystitis-carcinoma sequence. Clin Transl Med, 2020, 10(2): e97. doi: 10.1002/ctm2.97.
|
| 25. |
Shukla R, Tsuchiya Y, Behari A, et al. Metagenomic analysis of biliary microbial flora in patients with gallbladder cancer or gallstones-associated chronic cholecystitis. Cancer Invest, 2024, 42(6): 478-490.
|
| 26. |
Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res, 2020, 30(6): 492-506.
|
| 27. |
Choi SJ, Kim Y, Jeon J, et al. Association of microbial dysbiosis with gallbladder diseases identified by bile microbiome profiling. J Korean Med Sci, 2021, 36(28): e189. doi: 10.3346/jkms.2021.36.e189.
|
| 28. |
Sepe LP, Hartl K, Iftekhar A, et al. Genotoxic effect of Salmonella paratyphi A infection on human primary gallbladder cells. mBio, 2020, 11(5): e01911-20. doi: 10.1128/mBio.01911-20.
|
| 29. |
Scanu T, Spaapen RM, Bakker JM, et al. Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma. Cell Host Microbe, 2015, 17(6): 763-774.
|
| 30. |
Zhou D, Wang JD, Weng MZ, et al. Infections of Helicobacter spp. in the biliary system are associated with biliary tract cancer: a meta-analysis. Eur J Gastroenterol Hepatol, 2013, 25(4): 447-454.
|
| 31. |
Nagaraja V, Eslick GD. Systematic review with meta-analysis: the relationship between chronic Salmonella typhi carrier status and gall-bladder cancer. Aliment Pharmacol Ther, 2014, 39(8): 745-750.
|
| 32. |
Pragasam AK, Maurya S, Jain K, et al. Invasive Salmonella Typhimurium colonizes gallbladder and contributes to gallbladder carcinogenesis through activation of host epigenetic modulator KDM6B. Cancer Lett, 2025, 618: 217621. doi: 10.1016/j.canlet.2025.217621.
|
| 33. |
Liu S, Li W, Chen J, et al. The footprint of gut microbiota in gallbladder cancer: a mechanistic review. Front Cell Infect Microbiol, 2024, 14: 1374238. doi: 10.3389/fcimb.2024.1374238.
|
| 34. |
Fox JG, Ge Z, Whary MT, et al. Helicobacter hepaticus infection in mice: models for understanding lower bowel inflammation and cancer. Mucosal Immunol, 2011, 4(1): 22-30.
|
| 35. |
Lee HJ, Park SH, Han SY, et al. Differences in the biliary microbiome between biliary tract cancer and benign biliary disease. Microorganisms, 2026, 14(1): 208. doi: 10.3390/microorganisms14010208.
|
| 36. |
Kirishima M, Yokoyama S, Matsuo K, et al. Gallbladder microbiota composition is associated with pancreaticobiliary and gallbladder cancer prognosis. BMC Microbiol, 2022, 22(1): 147. doi: 10.1186/s12866-022-02557-3.
|
| 37. |
Wang L, Qiao W, Zhen X, et al. Targeting the gut-liver axis in cholangiocarcinoma: mechanisms, therapeutic advances, and future directions. Front Oncol, 2025, 15: 1646897. doi: 10.3389/fonc.2025.1646897.
|
| 38. |
Zhang Y, Zhang S. Oral microbiota and biliary tract cancers: unveiling hidden mechanistic links. Front Oncol, 2025, 15: 1585923. doi: 10.3389/fonc.2025.1585923.
|
| 39. |
Lederer AK, Rasel H, Kohnert E, et al. Gut microbiota in diagnosis, therapy and prognosis of cholangiocarcinoma and gallbladder carcinoma-a scoping review. Microorganisms, 2023, 11(9): 2363. doi: 10.3390/microorganisms11092363.
|
| 40. |
Zhu C, Wang Y, Zhu R, et al. Gut microbiota and metabolites signatures of clinical response in anti-PD-1/PD-L1 based immunotherapy of biliary tract cancer. Biomark Res, 2024, 12(1): 56. doi: 10.1186/s40364-024-00607-8.
|
| 41. |
Blake SJ, Wolf Y, Boursi B, et al. Role of the microbiota in response to and recovery from cancer therapy. Nat Rev Immunol, 2024, 24(5): 308-325.
|
| 42. |
Simpson RC, Shanahan ER, Scolyer RA, et al. Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol, 2023, 20(10): 697-715.
|
| 43. |
Geller LT, Barzily-Rokni M, Danino T, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science, 2017, 357(6356): 1156-1160.
|
| 44. |
Wu B, Quan C, He Y, et al. Targeting gut and intratumoral microbiota: a novel strategy to improve therapy resistance in cancer with a focus on urologic tumors. Expert Opin Biol Ther, 2024, 24(8): 747-759.
|
| 45. |
Wang K, Wang S, Qin X, et al. The causal relationship between gut microbiota and biliary tract cancer: comprehensive bidirectional Mendelian randomization analysis. Front Cell Infect Microbiol, 2024, 14: 1308742. doi: 10.3389/fcimb.2024.1308742.
|
| 46. |
Wang X, Liu X, Niu W, et al. Association of biliary microflora dysbiosis with cholangiocarcinoma: a single-center study. Front Microbiol, 2025, 16: 1666272. doi: 10.3389/fmicb.2025.1666272.
|
| 47. |
Mizutani H, Fukui S, Oosuka K, et al. Biliary microbiome profiling via 16 S rRNA amplicon sequencing in patients with cholangiocarcinoma, pancreatic carcinoma and choledocholithiasis. Sci Rep, 2025, 15(1): 16966. doi: 10.1038/s41598-025-00976-6.
|
| 48. |
Wang L, Zhao H, Wu F, et al. Bile-liver phenotype: exploring the microbiota landscape in bile and intratumor of cholangiocarcinoma. Comput Struct Biotechnol J, 2025, 27: 1173-1186.
|
| 49. |
Ye C, Zhang B, Lin Y, et al. Characteristics of gut microbiota and metabolites in extrahepatic cholangiocarcinoma and their prognostic value for resectable lesions. Front Cell Infect Microbiol, 2025, 15: 1523863. doi: 10.3389/fcimb.2025.1523863.
|
| 50. |
Austin GI, Korem T. Planning and analyzing a low-biomass microbiome study: a data analysis perspective. J Infect Dis, 2026, 233(1): 76-86.
|
| 51. |
Sirasani JP, Gardner C, Jung G, et al. Bioinformatic approaches to blood and tissue microbiome analyses: challenges and perspectives. Brief Bioinform, 2025, 26(2): bbaf176. doi: 10.1093/bib/bbaf176.
|
| 52. |
Chia M, Pop M, Salzberg SL, et al. Challenges and opportunities in analyzing cancer-associated microbiomes. Cancer Res, 2025, 85(19): 3584-3595.
|
| 53. |
Yao Y, Zhu Y, Chen K, et al. Microbiota in cancer: current understandings and future perspectives. Signal Transduct Target Ther, 2026, 11(1): 39. doi: 10.1038/s41392-025-02335-3.
|
| 54. |
El Tekle G, Garrett WS. Bacteria in cancer initiation, promotion and progression. Nat Rev Cancer, 2023, 23(9): 600-618.
|